Date:4/1/2008

re detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.

'/>"/>

SOURCE Millennium Biotechnologies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
2. Millennium Over-Delivers on 2007 Goals and Financial Guidance
3. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
4. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
5. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
6. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
7. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
10. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
11. Life Sciences Leader Joins Millennium Board of Directors